Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12349775 | 1.00 | CYP3A4 (0.38) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL12349778 | 0.92 | ADRB3 (0.41) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL8104803 | 0.92 | ADRB3 (0.41) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL12349810 | 0.92 | ADRB3 (0.41) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL13617075 | 0.91 | ADRB3 (0.42) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL2239474 | 0.91 | ADRB3 (0.42) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL7812408 | 0.91 | ADRB3 (0.42) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL2239472 | 0.91 | ADRB3 (0.42) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL2239478 | 0.91 | ADRB3 (0.42) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL17399734 | 0.88 | ADRB3 (0.33) | CYP3A4ADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343477-B2 | Viricides; serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, MRPS23, HCCS | CYP3A4 1993/4885ADRB3 3003/4885ADRA2B 4031/4885 |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | CYP3A4 1719/4885ADRB3 3491/4885ADRA2B 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.